Patents Represented by Attorney Mario A. Monaco
  • Patent number: 4942235
    Abstract: A unique process for preparing certain (2R-trans)hexahydroaroquinolizines, especially (2R-trans)-N-[2-(1,3,4,6,7,12b-hexahydro-2'-oxospiro[aro-[2,3-a]-quinolizi ne-2,4'-imidazolidin]-3'-yl)ethyl)-methanesulfonamide from (2R-trans)-N-[2-[(2-cyano-(1,3,4,6,7,12b-hexahydro-aro-[2,3-a]quinolizin-2 -yl)amino]ethyl]methanesulfonamide is described.
    Type: Grant
    Filed: March 16, 1989
    Date of Patent: July 17, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Ann E. DeCamp, Ralph P. Volante, Anthony O. King, Ichiro Shinkai
  • Patent number: 4814501
    Abstract: Pyrolysis of substituted salicylate O(N,N-dialkyl)thiocarbamates yielded the corresponding N,N-dialkyl-2-(methylthio)benzamide. Similarly, substituted 6-azasalicylate O(N,N-dialkyl)thiocarbamates yielded the corresponding N,N-dialkyl-2-(methylthio)-6-aza-benzamide.
    Type: Grant
    Filed: December 28, 1987
    Date of Patent: March 21, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Bruce E. Witzel, Robert K. Baker, Philippe L. Durette, Robert A. Frankshun
  • Patent number: 4808718
    Abstract: Novel fused polycyclic and bridged compounds are disclosed which are useful as calcium entry blockers.
    Type: Grant
    Filed: May 6, 1986
    Date of Patent: February 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Wasyl Halczenko, Brian T. Phillips
  • Patent number: 4800211
    Abstract: 3-Hydroxybenzo[b]thiophene-2-carboxamide derivatives have been prepared by:(1) treating a substituted 2-halobenzoate with a thioacetamide.(2) treating a substituted thiosalicylate with an appropriately substituted haloacetamide; and(3) further synthetic modification of compounds prepared above.These compounds have been found to be effective inhibitors of both cyclooxygenase and lipoxygenase and thereby useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandins and/or leukotriene mediated diseases.
    Type: Grant
    Filed: August 18, 1986
    Date of Patent: January 24, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Allan N. Tischler, Philippe L. Durette, Bruce E. Witzel, Thomas J. Lanza, Jr.
  • Patent number: 4798823
    Abstract: New cyclosporin analogs with modified "C-9 amino acids" have been made and are found to be effective immunosuppressive agents.
    Type: Grant
    Filed: June 3, 1987
    Date of Patent: January 17, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Bruce E. Witzel
  • Patent number: 4778818
    Abstract: Substituted cinnamyl-2,3-dihydrobenzofurans and analogs were prepared from the nucleophlic substitution of a cinnamylhalide with a 2,3-dihydrobenzofuran anion or an analog thereof. These compounds were found to be potent topical anti-inflammatory agents.
    Type: Grant
    Filed: April 17, 1987
    Date of Patent: October 18, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Michael N. Chang, Norman P. Jensen, Milton L. Hammond, Robert A. Zambias, John McDonald, Kathleen M. Rupprecht
  • Patent number: 4748153
    Abstract: Compounds having somatostatin-like activity have been found to be useful as local anti-inflammatory agents in the treatment of such conditions as, for example, psoriasis, eczema, seborrhea, and other localized inflammatory and allergic conditions. Particularly useful are cyclic and bridged somatostatin analogs.
    Type: Grant
    Filed: September 2, 1987
    Date of Patent: May 31, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Evan R. Morgan, Daniel F. Veber, Sanford L. Steelman
  • Patent number: 4743694
    Abstract: The addition of organolithium to dimethylhydrazones of certain ethers of a-hydroxyaldehydes results in the synthesis of threo- or erythro- intermediates readily convertible to threo- or erythro-2-amino alcohols.
    Type: Grant
    Filed: April 11, 1986
    Date of Patent: May 10, 1988
    Assignee: Mercek & Co., Inc.
    Inventor: David A. Claremon
  • Patent number: 4735956
    Abstract: Novel substituted 4-heteroaryl-1,4-dihydropyridine compounds useful as calcium channel blockers, pharmaceutical compositions therof, and methods of treatment are disclosed.
    Type: Grant
    Filed: September 13, 1985
    Date of Patent: April 5, 1988
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Wasyl Halczenko, George D. Hartman, Brian T. Phillips
  • Patent number: 4731444
    Abstract: There are disclosed bicyclic lactams and derivatives thereof which are useful as converting enzyme inhibitors and as antihypertensives.
    Type: Grant
    Filed: August 3, 1984
    Date of Patent: March 15, 1988
    Assignee: Merck & Co., Inc.
    Inventors: William H. Parsons, Matthew J. Wyvratt, Jr.
  • Patent number: 4680392
    Abstract: The invention in its broad aspects relates to caprolactam derivatives which are useful as angiotensin converting enxyme inhibitors and as antihypertensives.
    Type: Grant
    Filed: May 19, 1986
    Date of Patent: July 14, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Elbert E. Harris, Arthur A. Patchett, Eugene D. Thorsett
  • Patent number: 4677102
    Abstract: There are disclosed novel diazapines and derivatives thereof which are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: February 7, 1986
    Date of Patent: June 30, 1987
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David E. McClure, David A. Claremon
  • Patent number: 4675321
    Abstract: Pharmaceutical compositions of specific substituted pyrimidines and methods of treatment of certain cardiovascular disorders are disclosed. Also disclosed are novel substituted acrylated pyrimidines which are useful as calcium channel blockers.
    Type: Grant
    Filed: February 7, 1986
    Date of Patent: June 23, 1987
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Steven M. Pitzenberger, David E. McClure
  • Patent number: 4670578
    Abstract: Crystalline salts of (R,S)-pivaloyloxyethyl esters of (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine and processes for their preparation are disclosed.
    Type: Grant
    Filed: August 29, 1983
    Date of Patent: June 2, 1987
    Assignee: Merck & Co., Inc.
    Inventors: John Budavari, Edward J. J. Grabowski
  • Patent number: 4665094
    Abstract: Hydroxyalkyl-phenoxy-propan-2-olamines and novel esters thereof are oculoselective .beta.-blockers useful in the treatment of elevated intraocular pressure with little or no effect on the pulmonary or cardiovascular system.
    Type: Grant
    Filed: August 29, 1985
    Date of Patent: May 12, 1987
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Patent number: 4656190
    Abstract: Indene derivatives have been found to have potent and specific PAF (Platelet-Activating-Factor) antagonistic activities and are thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, and adult respiratory distress syndrome.
    Type: Grant
    Filed: November 14, 1983
    Date of Patent: April 7, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Tsung-Ying Shen, Shu S. Yang, San-Bao Hwang
  • Patent number: 4590201
    Abstract: Novel 5-amino or substituted amino 1,2,3-triazoles are disclosed as having anticoccidial activity. The compounds are useful for controlling coccidiosis when administered in minor quantities to animals, in particular to poultry, usually in admixture with animal sustenance.
    Type: Grant
    Filed: February 2, 1984
    Date of Patent: May 20, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Richard J. Bochis, John C. Chabala, Michael H. Fisher
  • Patent number: 4581345
    Abstract: There are disclosed novel avermectin 8,9-cyclopropyl compounds (also referred to as 8,9-dihydro-8,9-methano avermectin compounds). The 8,9-cyclopropyl compounds are prepared by treating an avermectin compound with an iodohalomethane compound in the presence of an activated form of zinc. The avermectin 8,9-cyclopropyl compounds have utility as anti-parasitic agents and compositions for that use are also disclosed. The compounds are also highly potent insecticides against agricultural pests.
    Type: Grant
    Filed: April 8, 1985
    Date of Patent: April 8, 1986
    Assignee: Merck & Co., Inc.
    Inventor: Matthew J. Wyvratt, Jr.
  • Patent number: 4579864
    Abstract: There are disclosed novel avermectin and milbemycin compounds wherein the 13-position is oxidized to a keto function. The 13-keto derivatives are prepared from the 13-hydroxy compounds by oxidizing the 13-position with a suitable oxidizing agent. The avermectin and milbemycin 13-keto derivatives are active in their own right and also serve as intermediates in the preparation of 13-imino and 13-amino derivatives. The 13-keto, imino and amino compounds have utility as anti-parasitic agents and compositions for that use are also disclosed. The compounds are also highly potent insecticides against agricultural pests.
    Type: Grant
    Filed: June 11, 1984
    Date of Patent: April 1, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Bruce O. Linn, Helmut H. Mrozik
  • Patent number: 4578390
    Abstract: Hydroxybenzylamino derivatives have been prepared from an appropriate hydroxybenzaldehyde and an amine followed by reduction. These compounds are found to be active topical anti-inflammatory agents.
    Type: Grant
    Filed: April 13, 1983
    Date of Patent: March 25, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Norman P. Jensen, Michael N. Chang